Teleflex to Introduce the New Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump & the Product Portfolio from the Recently Acqu...

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies for critical care, urology and surgery, will showcase its complex PCI product portfolio recently acquired from the purchase of Vascular Solutions and the new Arrow® AC3 Optimus™ Intra-Aortic Balloon Pump (IABP) at the EuroPCR being held in Paris, France on May 16-19, 2017.

With the recent acquisition of Vascular Solutions, Teleflex now offers a full line of products that give interventional cardiologists the tools they need to handle routine and complex cases, resulting in improved outcomes for patients. Cardiologists worldwide rely on the quality and proven clinical effectiveness of products, such as the GuideLiner® Catheter Platform, TrapLiner™ Catheter, Turnpike® Catheter, Twin-Pass® Torque Dual Access Catheter, and R350™ Guidewire.

Teleflex will also introduce the new Arrow® AC3 Optimus IABP. This device helps a weakened heart pump blood and can deliver IABP therapy to a broad range of patients, even those not previously considered candidates for IABP therapy. Clinicians may use the pump on patients with the most severe arrhythmias or with heart rates as high as 200 beats per minute.1, 2

The Arrow® AC3 Optimus™ IABP has a third-generation AutoPilot® Mode, which uses proprietary algorithms to address key clinical challenges and to simplify the delivery of IABP therapy.3 In AutoPilot® Mode, the Arrow® AC3 Optimus™ IABP automatically adjusts timing and triggering parameters, freeing clinicians to focus on the patient rather than the pump. In addition, the Arrow® AC3 Optimus™ IABP includes several exclusive algorithms, such as WAVE® Inflation Timing, Deflation Timing Management, and Best Signal Analysis, which optimize key functions of the IABP to deliver therapy to the most challenging patients.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch® and Weck® – trusted brands united by a common sense of purpose.

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.

Teleflex, the Teleflex logo, Arrow, AC3 Optimus, AutoPilot, Deknatel, Hudson RCI, LMA, Pilling, R350, Rusch, WAVE, and Weck are trademarks or registered trademarks of Teleflex Incorporated or its affiliates, in the U.S. and/or other countries.© 2017 Teleflex Incorporated. All rights reserved.

References:

1. Schreuder J, Castiglioni A, Donelli A, et al. Automatic intraaortic balloon pump timing using an intra beat dicrotic notch prediction algorithm. Ann Thorac Surg. 2005;79(3):1017-1022. Study sponsored by Teleflex.
2. Donelli A, Jansen JRC, Hoeksel B, et al. Performance of a real-time dicrotic notch detection and prediction algorithm in arrhythmic human aortic pressure signals. J Clin Monit. 2002;17(3-4):181-185. Study sponsored by Teleflex.
3. Torracca, L. Overcoming electro-surgical inference in IABP therapy with the combined use of AutoPilot and FiberOptix IAB sensor signal. 2007. (Case report, data on file). Study sponsored by Teleflex.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170515006618/en/

Teleflex IncorporatedJake ElguiczeTreasurer and Vice President, Investor Relations610-948-2836orMartina Teichmann-ZindlerSenior Director Marketing Communications International+49 (0)[e-mail]